Javascript must be enabled to use this site. Please enable Javascript in your browser and try again. Apply to become a Senior Planet sponsored athlete to motivate ...
Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in systemic lupus erythematosus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback